A Smarter Future for Veterinary Medicine Starts Here
Our mission is simple: make pet diabetes care easier, more precise,
and stress-free for pets, veterinarians, and pet owners alike.
Why we built Adapet CGM A1 from the ground up to provide:
Our Vision and Mission
“Technology Should Adapt to Veterinary
Medicine, Not the Other Way Around.”
Our Vision
To create a world where every pet has access to scientific,standardized, and high-quality medical care, ensuring theirhealth, welfare, and fostering a harmonious relationshipbetween humans and animals.
To create a world where every pet has access to scientific,standardized, and high-quality medical care, ensuring theirhealth, welfare, and fostering a harmonious relationshipbetween humans and animals.
Our Mission
We focus on prevention, early detection, and treatment,offering a comprehensive approach to pet care to ensure thatpets receive the same level of care as family members.
We focus on prevention, early detection, and treatment,offering a comprehensive approach to pet care to ensure thatpets receive the same level of care as family members.
Our Value
Compassion | Excellence | Collaboration | Innovation | Integrity |
Compassion | Excellence | Collaboration | Innovation | Integrity |
Regonzied Partnet of
Milestone
2022
CGM technology spin-off from Jointown.
2023
Producitization of CGM A1 and Mobile APP.
2024
- UL and CSA approved.
- Completion of 100 clinic trial tests in North American.
- Recognized partner of the CVMA.
2025
Offical launch of CGM A1.
Investment Plan
We plan to allocate CAD 5,000,000 to advance Adapet Medical's development in pet medical technology, enhance product stability, and ensure precision. In 2025, we will invest an additional CAD 1,000,000 to support the improvement and exchange of global pet medical education.
Production Plan
Adapet Medical closely collaborates with Fortune 500 manufacturers. Foxconn, which have extensive production experienceand strong technical capabilities. This partnership enhances the competitive advantage of our products.
G2M Plan
Trial Tests
A head-to-head study was conducted to evaluate the accuracy of Adapet A1 real-time continuous glucose monitoring system. it exhibited an overall MARD value less than 10% and product survival rate reach to 98% during hospitalization.
0%
98 % of products that remain functional or meet quality standards over a specified period under normal usage conditions.
0%
The Mean Absolute Relative Difference (MARD%) for all subjects was less than 10%.
0%
The CGM measurements and BGM measurements achieved a 20/20% match rate of 75%.
0%
In the Clarke Error Grid Analysis, 98% of the data points fell within zones A and B.
Differentiators
3 Core Technologies
Semi-permeable membrane, enzymetechnology, advanced algorithm
Regulatory Compliance
Received 13 certificates, e.g. UL, CSA, CE, etc.
R&D Expertise
Members with solid technical backgrounds and 20 yrs of industry experience.
IP Protection
120+patent applications, 29 PCT applications, 106 trademarks, 8 software copyrights
Global Partnership
Recognized Partner of the CVMA, enter 5 + Countries
3 Core Technologies
Semi-permeable membrane, enzymetechnology, advanced algorithm
Regulatory Compliance
Received 13 certificates, e.g. UL, CSA, CE, etc.
R&D Expertise
Members with solid technical backgrounds and 20 yrs of industry experience.
IP Protection
120+patent applications, 29 PCT applications, 106 trademarks, 8 software copyrights
Global Partnership
Recognized Partner of the CVMA, enter 5 + Countries